Functional impact of gluteal tendinopathy: A secondary cross-sectional analysis of baseline data from the LEAP randomised clinical trial.

Everything was measured once, at the start of the trial, before treatment. The study describes what people were limited by; it cannot say what caused the problem or whether any treatment changes it. 82% of participants were women, which reflects who gets gluteal tendinopathy, but the findings may not apply to men. Sorting the named activities into categories involved the researchers' judgement, so another group of researchers might have made slightly different categories. Participants volunteered for a trial after seeing advertisements, and most were moderately or highly active, so they may not represent patients who are much less active or more limited. Only 4 people fell into the sedentary activity group, so the finding that activity level made no difference to PSFS scores rests on very little data at that end.

The authors declare no competing interests. The text supplied contains no funding statement, so it is not possible to tell who paid for the trial or whether the funder had any role in it.

Do not read this as evidence about treatment. Everyone was measured once, before any treatment began, so the average score of 4.6 out of 10 describes how limited these people were at the start of the LEAP trial, not whether any treatment helped them.